Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients Hospitalized With Pneumonia Due To COVID-19 or Other Respiratory Infections.

NCT05123755 is registered in ClinicalTrials.gov with Vasomune Therapeutics, Inc. as lead sponsor.

NCT NCT05123755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05123755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients Hospitalized With Pneumonia Due To COVID-19 or Other Respiratory Infections.
Lead sponsor
Vasomune Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 20, 2021
Completion date
September 30, 2026
Enrollment
60 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, covid-19 acute respiratory distress syndrome, pneumonia, pneumonia, viral, respiratory infection, viral or bacterial infections